1. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties
- Author
-
Laura Conesa-Milián, Miguel Carda, Juan Murga, Eva Falomir, and J. Alberto Marco
- Subjects
PD-L1 ,Ureas ,Angiogenesis ,Angiogenesis Inhibitors ,Antineoplastic Agents ,01 natural sciences ,Docking ,Flow cytometry ,HeLa ,03 medical and health sciences ,Western blot ,Cell Line, Tumor ,Neoplasms ,Bibenzyls ,Drug Discovery ,medicine ,Humans ,Immunologic Factors ,Urea ,Kinase activity ,Protein Kinase Inhibitors ,Cell Proliferation ,030304 developmental biology ,Pharmacology ,Tube formation ,0303 health sciences ,medicine.diagnostic_test ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,General Medicine ,biology.organism_classification ,Vascular Endothelial Growth Factor Receptor-2 ,0104 chemical sciences ,Molecular Docking Simulation ,VEGFR-2 ,HEK293 Cells ,Biochemistry ,Docking (molecular) ,Immunotherapy ,Drug Screening Assays, Antitumor ,Tyrosine kinase - Abstract
By means of docking studies, seventeen compounds T.1-T17 have been designed and evaluated as multitarget inhibitors of VEGFR-2 and PD-L1 proteins in order to overcome resistance phenomena offered by cancer. All these designed molecules display a urea moiety as a common structural feature and eight of them (T.1-T8) further contain a 1,2,3-triazol moiety. The antiproliferative activity of these molecules on several tumor cell lines (HT-29, MCF-7, HeLa, A549, HL-60), on the endothelial cell line HMEC-1 and on the non-tumor cell line HEK-293 has been determined. The urea derivatives were also evaluated for their antiangiogenic properties, whereby their ability to inhibit tubulogenesis and kinase activity employing flow cytometry, ELISA, immunofluorescence and western blot techniques was measured. In addition, these techniques were also employed to investigate the immunomodulator action of the synthetic compounds on the inhibition of PD-L1 and c-Myc proteins. Compound T.2, 1-(3-chlorophenyl)-3-(2-(4-(4-methoxybenzyl)-1H-1,2,3-triazol-1-yl)ethyl)urea, has shown similar results to sorafenib in both down-regulation of VEGFR-2 and inhibition of the kinase activity of this receptor. Furthermore, compound T.14, (E)-1-(4-chlorophenyl)-3-(3-(4-methoxystyryl)phenyl)urea, improves the effect of T.2 as regards tube formation of endothelial cells and inhibition of VEGFR-2 tyrosine kinase activity. In addition, T.14 improves the effect of the experimental drug BMS-8 in the inhibition of PD-L1 and c-Myc proteins.
- Published
- 2019
- Full Text
- View/download PDF